News stories about Dicerna Pharmaceuticals (NASDAQ:DRNA) have been trending somewhat positive on Thursday, according to Accern. Accern scores the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Dicerna Pharmaceuticals earned a media sentiment score of 0.06 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.8073800129943 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:
- Dicerna Pharma (DRNA) Announces Proposed Common Share Offering (streetinsider.com)
- With -20.9% EPS Drop, Should Dicerna Pharmaceuticals Inc’s (NASDAQ:DRNA) Recent Track Record Be A Cause Of Concern? (finance.yahoo.com)
- Dicerna Announces Pricing of Follow-On Public Offering of Common Stock (finance.yahoo.com)
- Head-To-Head Comparison: Dicerna Pharmaceuticals (DRNA) and Its Peers (americanbankingnews.com)
- Head to Head Contrast: Dicerna Pharmaceuticals (DRNA) and Its Rivals (americanbankingnews.com)
Dicerna Pharmaceuticals (NASDAQ DRNA) traded up $0.34 during trading on Thursday, reaching $7.84. 177,200 shares of the company were exchanged, compared to its average volume of 176,034. Dicerna Pharmaceuticals has a fifty-two week low of $2.42 and a fifty-two week high of $10.24.
DRNA has been the subject of a number of recent research reports. Zacks Investment Research lowered shares of Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. ValuEngine upgraded shares of Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, November 2nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective (up from $6.00) on shares of Dicerna Pharmaceuticals in a research note on Friday, November 3rd. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $6.81.
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.